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ERRATA
KIRIBAYSHI K, MASAKI T, NAITO T, OGAWA T, ITO T, YORIOKA N, KOHNO N: Angiotensin II induces fibronectin
expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int 67:1126–1135, 2005
In the above-mentioned article, on page 1134, the reprint request lines should read as follows:
Reprint requests to Takao Masaki, M.D., Ph.D., Department of Molecular and Internal Medicine,
Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, 1-2-3-,
Kasumi, Minami-ku, Hiroshima 734-8551, Japan.
E-mail: masaki@hiroshima-u.ac.jp
The authors apologize for the error.
ROBINSON BM, JOFFE MM, BERNS JS, PISONI RL, PORT, FK, FELDMAN HI: Anemia and mortality in hemodialysis
patients: Accounting for morbidity and treatment variables updated over time. Kidney Int 68:2323–2330, 2005
In the above-mentioned article, on page 2325, Table 1 should appear as below:
Table 1. Variables considered to plausibly confound the association
of hemoglobin with mortality
Recorded DOPPS enrollment
Demographics
Sex
Race/ethnicity
ESRD cause
Morbidity and other characteristicsa
Atherosclerotic cardiovascular disease
Congestive heart failure
Hypertension
Left ventricular hypertrophy
Cancer, non-skin
Gastrointestinal illness
Neurologic illness
Pulmonary illness
Psychiatric illness
Smoking history
Do-not-resuscitate status
Functional status (ordered variable)
Updated during each DOPPS intervalb
Demographics
Age
ESRD vintage (years since first HD)
Laboratory measures
Albumin
Bicarbonate
Calcium
Calcium-phosphate product
Cholesterol, total
Creatinine
Ferritin
Hemoglobin (prior)
Parathyroid hormone
Phosphate
Potassium
Also, on page 2327, in the legend to Table 3, the text should read: “aAdjusted for variables
denoted by italics in Table 1.”
The Editorial Office apologizes for these errors.
KURTZ I, NGUYEN MK: Evolving concepts in the quantitative analysis of the determinants of the plasma water sodium
concentration. Kidney Int 68:1982–1993, 2005
In the above-mentioned article, on page 1986, lefthand column, paragraph 2, line 9 from the
bottom, the text should read: “TBW −151.3 + 4.2 + 155.6.”
The Editorial Office apologizes for the error.
Table 1. (continued)
Transferrin saturation
White blood cell count
Medications
Epoetin dose (units/week)
Epoetin administration route (intravenous or subcutaneous)
Parenteral iron dose (normalized 6-month cumulative)
Parenteral iron administrations (normalized 6-month cumulative)
Dialysis parameters
HD duration, delivered
HD duration, prescribed
Systolic blood pressure, pre-dialysis
Systolic blood pressure, post-dialysis
Kt/V, delivered
Urea reduction ratio, delivered
Ultrafiltration volume, removed
Other
Kidney transplantation, active listing for
Nutritional supplement, currently prescribed
Residual renal function
Medical eventsc
Hospitalized days
Hospitalizations
Outpatient medical procedures
Vascular access procedures
Consideration for multivariable model inclusion: ESRD vintage was the des-
ignated time scale for our survival models. All other variables listed above were
tested for P ≤ 0.10 for the association with mortality in the adjusted 3-month-
lagged model. Those variables designated by italics met this criterion and were
included in all adjusted models.
aDichotomous (yes/no) unless otherwise indicated.
bSee text for methods used by the DOPPS to update variables. In our multi-
variable models, levels of time-updated potentially confounding variables were
the most recent values prior to time-updated Hb levels.
cCumulative over most recent 3 months.
dVariables for smoking history, potassium level, and residual renal function
had P > 0.20 for the unadjusted association with mortality.
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MICHAEL L, SWEENEY DE, DAVIES JA: A role for microfilament-based contraction in branching morphogenesis of
the ureteric bud. Kidney Int 68:2010–2018, 2005
In the above mentioned article, on pages 2014 and 2015, Figure 4 and its legend should appear
as follows:
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Fig. 4. The effect on ureteric bud morphogenesis of inhibiting the rho kinase ROCK. (A and B) The ROCK inhibitors Y27632 and H1152 each
inhibit ureteric bud branching. Inhibition of ROCK causes ureteric buds to develop an under-branched, bloated morphology (D) compared to
controls (C). Staining is for calbindin D-28K. Antilaminin staining shows that nephrons (arrows) develop from the mesenchyme as normal in both
control kidneys (E) and those grown in 5 to 10 lmol/L Y27632 (F). Phalloidin staining shows that the strong staining of the tips, characteristic of
control kidneys (G) is lost in Y27632 and the filamentous actin within the bud becomes disorganized throughout and weaker in the tips than in the
stalks (H). (I and J) Y27632 produces its morphogenetic effects with no significant effects on either cell proliferation or on apoptosis in the bud
tips. In contrast, H1152 does significantly increase both proliferation and apoptosis.
The authors apologize for the error.
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SHAMSHIRSAZ AA, BEKHEIRNIA MR, KAMGAR M, JOHNSON AM, MCFANN K, CADNAPAPHORNCHAI M,
NOBAKHTHAGHIGHI N, SCHRIER RW: Autosomal-dominant polycystic kidney disease in infancy and childhood: Pro-
gression and outcome. Kidney Int 68:2218–2224, 2005
In the above-mentioned article, on page 2218, the authors should be listed as follows:
ALIREZA ABDOLLAH SHAMSHIRSAZ, MIR REZA BEKHEIRNIA, MOHAMMAD KAMGAR, ANN M. JOHNSON, KIM
MCFANN, MELISSA CADNAPAPHORNCHAI, NILOOFAR NOBAKHTHAGHIGHI, and ROBERT W. SCHRIER
The authors apologize for the error.
STICHTENOTH DO, MARHAUER V, TSIKAS D, GUTZKI F-M, FRO¨LICH JC: Effects of specific COX-2-inhibition on
renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 68:2197–2207, 2005
In the above-mentioned article, on page 2200, the legend to Figure 2 should read: Effects of
celecoxib 200 mg twice a day (b.i.d.), indomethacin 50 mg three times a day (t.i.d.), or placebo
on plasma aldosterone concentration on day 5 of treatment before (pre) and 5, 10, 30, 60, and
120 minutes after 20 mg intravenously.
On page 2203, Table 2 should appear as below:
Table 2. Effects of celecoxib 200 mg twice a day (b.i.d.), indomethacin 50 mg three times a day (t.i.d.) or placebo on excretion of prostaglandin E2
(PGE2), 7a-hydroxy-5,11-diketotetranor-prosta-1,16-dioic acid (PGE-M), 6-keto-PGF1a , 2,3-dinor-6-keto-PGF1a , and 2,3-dinor-thromboxane B2
(TxB2) in 2-hour urines on the day 5 of treatment before and after 20 mg furosemide intravenously
PGE2 nmol/mol PGE-M nmol/mol 6-keto-PGF1a nmol/mol 2,3-dinor-6-keto-PGF1a 2,3-dinor-TxB2 nmol/mol
creatinine creatinine creatinine nmol/mol creatinine creatinine
Placebo
2 hours before furosemide 78.9 ± 46.7 330.8 ± 181.1 34.6 ± 19.2 58.9 ± 31.9 134.2 ± 75.7
2 hours after furosemide 78.8 ± 39.4 795.6 ± 413.0f 27.7 ± 17.8e 36.7 ± 23.5e 104.9 ± 97.0
Celecoxib
2 hours before furosemide 65.3 ± 62.6c 217.8 ± 107.3c 19.5 ± 11.7a 14.7 ± 7.4b 112.3 ± 63.7d
2 hours after furosemide 45.6 ± 19.3a 536.2 ± 276.4c,f 14.8 ± 7.9a,c 20.0 ± 15.8a,c 108.2 ± 58.9d
Indomethacin
2 hours before furosemide 33.0 ± 9.9b 146.9 ± 85.2b 20.3 ± 13.9a 15.5 ± 33.4b 16.9 ± 10.7b
2 hours after furosemide 34.6 ± 12.0b 337.9 ± 182.7b,f 10.5 ± 7.8b,e 5.4 ± 3.9b 19.7 ± 15.5a
Mean ± SD (N = 16).
aP < 0.05; bP < 0.001 versus placebo, same collection period; cP < 0.05; dP < 0.001 versus indomethacin, same collection period; eP < 0.05; and fP < 0.001 vs. 2-hour urine before furosemide,
same medication.
On page 2204, the legend to Figure 7 should read: Effects of celecoxib 200 mg twice a day (b.i.d.),
indomethacin 50 mg three times a day (t.i.d.), or 6-keto-PGF1a excretion in 24-hour urine on
day 4 of treatment.
The Editorial Office apologizes for these errors.
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